- Home
- CAN vs HELP Comparison
CAN vs HELP Comparison
Compare CAN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | HELP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Singapore | Canada |
| Employees | N/A | 50 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.9M | 504.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAN | HELP |
|---|---|---|
| Price | $0.17 | $7.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.21 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 10.7M | 1.6M |
| Earning Date | 05-19-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $3.76 |
| 52 Week High | $2.22 | $8.55 |
Technical Indicators
Market Signals| Indicator | CAN | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 25.12 | 63.68 |
| Support Level | N/A | $4.18 |
| Resistance Level | $0.56 | $8.50 |
| Average True Range (ATR) | 0.02 | 0.51 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.50 | 68.54 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.